Our data suggest that ICI may be less efficacious in BRAF V600E variant melanoma brain metastases but do not address the question of whether targeted therapy (combination BRAF and MEK inhibition) might be preferred to ICI in this patient population. The gene discussed is BRAF; the disease is melanoma.